Meloxicam Ratiopharm (Meloxicam)

Meloxicam selectively blocks the cyclooxygenase‑2 (COX‑2) enzyme, which is essential for producing prostaglandins that drive inflammation, pain and fever. By lowering prostaglandin levels, the drug diminishes the inflammatory response while preserving COX‑1 activity that protects the stomach lining.

The appropriate dose of Meloxicam Ratiopharm is determined by the prescribing clinician based on the patient’s condition, severity, age, renal and hepatic function, and other medications. Only a qualified health professional should set the dosage regimen.

Safety data for meloxicam in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the possible risk to the fetus or infant, and this decision must be made by a healthcare provider after careful evaluation.

To request Meloxicam Ratiopharm, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Meloxicam offers a relatively selective COX‑2 inhibition compared with non‑selective NSAIDs, which may result in a lower incidence of gastrointestinal irritation. However, it shares similar cardiovascular and renal risk profiles, so clinicians weigh these factors when choosing the most appropriate NSAID for a patient.

Meloxicam Ratiopharm tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Do not store in a humid environment such as a bathroom cabinet.

The medication is taken orally, usually with a full glass of water. It can be taken with or without food, but taking it with food may reduce stomach upset. Patients should follow the dosing instructions provided by their prescriber.

Serious risks include gastrointestinal ulceration or bleeding, severe skin reactions, liver injury, renal impairment, and increased risk of cardiovascular events such as heart attack or stroke. Patients should be monitored for these events, especially if they have pre‑existing risk factors.

Meloxicam should be avoided in individuals with known hypersensitivity to meloxicam or other NSAIDs, active gastrointestinal ulcer disease, severe heart failure, uncontrolled hypertension, or significant renal or hepatic impairment unless specifically directed by a physician.